Inhibiting the Inhibitors, PTP1B as a Therapeutic Target in Myocardial Infarction
Journal Title: Heart Research – Open Journal - Year 2018, Vol 5, Issue 1
Abstract
Biological systems self-regulate through cycles of activation and inactivation, the balance of which is critical in permitting or suppressing signaling cascades and their downstream consequences. Kinase signaling pathways are regulated through phosphorylation (activation) and dephosphorylation (inactivation) events. Hyperactivity of kinase pathways plays a causal and critical role in the development of cardiac pathologies, and as such, the development of pharmacological inhibitors has been an intense area of investigation. Conversely, enhancing the activity of suppressed, but potentially beneficial kinase activities present an alternative therapeutic avenue. In this context, kinase dephosphorylation by phosphatases results in inactivation and suppression of the pathway. Thus inhibiting the inhibitors provides a method by which to enhance the activity of selected pathways. The protein tyrosine phosphatase 1B (PTP1B) has been implicated as a therapeutic target in several diseases but was considered to be undruggable. More recent development of inhibitors with improved specificity and pharmacological properties along with identification of novel indications has sparked renewed interest. This mini-review summarises the current status of PTP1B inhibitors in clinical trials and in pre-clinical models for new indications; myocardial infarction and heart failure.
Authors and Affiliations
Lorna R. Fiedler
Keywords
Related Articles
- EP ID EP556021
- DOI 10.17140/HROJ-5-147
- Views 137
- Downloads 0
Clinical Trials of Coronary Stents in India: An Update
The Coronary Artery Disease (CAD) burden increased in Indian population and even it is increasing in young Indians. There are more ways to treat these patients and coronary stents are one of the option for them. In the p...
Short-term Cardio-Vascular Risk Score Changes in Type 2 Diabetic Patients on Empaglifozin: A Real-Life Clinical Experience
Objective: The aim of the study was to test both efficacy and safety of empaglifozin in type 2 diabetic out patients followed-up within a single institution. Materials and Methods: One hundred seventy-eight consecutive p...
Baseline Visual Acuity of Women with Diabetic Macular Edema is Worse than Men: A Case-Control Study
Purpose: To compare the baseline visual and anatomical parameters between the woman and men with diabetic macular edema (DME) who underwent intravitreal ranibizumab treatment. Materials and Methods: This was a retrospect...
Less is More: Benefit of Achieving Very Low Low-Density Lipoprotein-Cholesterol Levels on Cardiovascular Events
Low-density lipoprotein-cholesterol (LDL-C) reduction with statin therapy is one of the most pivotal interventions for atherosclerotic cardiovascular disease (ASCVD) prevention and treatment. The risk of coronary artery...
Treatment of Cardiac Hemochromatosis
Treatment of iron-overload states is important to prevent or reverse cardiac dysfunction.1-5 Removal of excess iron from the tissues in these patients reduces generation of free radicals, decreasing organ damage.6,7 Remo...